linjc16/ctgov huggingface dataset:
Home Telemonitoring System for Patients With Heart Failure vs Usual Care

Study Overview
=================
Brief Summary
-----------------
This randomized controlled clinical trial compares a home telemonitoring system (HTS) versus usual care during a 90 days follow-up period of Heart Failure (HF) ambulatory patients, in order to evaluate if the use of the HTS improves quality of life and HF related-knowledge. The study was reviewed and approved by the Methodological Committee and by the Research Ethics Committee from the Provincial Health System, according to the Declaration of Helsinki. Written informed consent was obtained before randomization.

Official Title
-----------------
Trial Clínico: Utilidad Del Telemonitoreo en Pacientes Con IC Como Medio de Apoyo Para la autogestión de la Enfermedad

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Device: Home Telemonitoring System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: were over 18 years with a primary diagnosis of HF, had been hospitalized at least once time as a consequence of a HF decompensation, had a Smartphone, had access to WiFi, had access to a weight scale and to a blood-pressure monitor Exclusion Criteria: illiterate patients, had learning difficulties, had a cognitive impairment sufficient to interfere with the use of the telemonitoring system, or had a severe depression that could interfere with their quality of life perception.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Telemonitoring<br> | Device: Home Telemonitoring System<br>* Home Telemonitoring System (HTS) The HTS consists of an App that daily collects measurements of weight, blood pressure, heart rate and symptoms (checklist of symptoms questions). The HTS processes the data and generates and sends an alert to the physicians if a risk situation occurs (measurements are outside of normal ranges). The App has also an educational functionality that allows learning about lifestyle, self-care and healthy habits for HF patients. For this purpose, the application: a) has a section that answers frequent questions, b) has a question and answer game about HF, and c) sends educational messages to the patients every day.<br>|
| No Intervention: Usual Care<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in quality of life through the Minnesota Living with Heart Failure Questionnaire (MLHFQ) |  | 3-month | 
| Changes in HF related knowledge through the Knowledge of CHF questionnaire |  | 3-month |
French National Database of Rare Dermatological Cancers

Study Overview
=================
Brief Summary
-----------------
Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes. CARADERM is a French prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are : to provide epidemiological, clinical and socio-economic characteristics of patients to identify new clinical or epidemiological prognostic factors for these rare cancers to evaluate the impact of various treatments on outcomes

Detailed Description
-----------------
CARADERM is a French national multidisciplinary project which will prospectively enroll from 37 French centers any patient presenting with Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment or cutaneous adnexal carcinoma. A structured and centralized database of clinical monitoring of patients will be established. Information captured will include clinical constitutional factors, factors linked to primary carcinoma, factors linked to lymph node involvement, American Joint Committee on Cancer (AJCC) stage at inclusion, recurrence patterns, therapeutic interventions (medical, surgical, radiotherapy and palliative strategies) with evaluation of response, date of death, date of latest news.

Official Title
-----------------
French National Database of Rare Dermatological Cancers: Merkel Cell Carcinoma, Inoperable or Metastatic Basal Cell Carcinoma, Cutaneous Adnexal Carcinomas

Conditions
-----------------
Adnexal Tumor of Skin, Merkel Cell Carcinoma, Advanced Basal Cell Carcinoma Requiring Systemic Treatment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma Exclusion Criteria: Subjects without Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma Patients refusal
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Merkel cell carcinoma<br> | |
| Advanced basal cell carcinoma<br> | |
| Cutaneous adnexal carcinomas<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence and natural history of the 3 types of rare skin cancers |  | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adnexal cutaneous carcinoma, Merkel cell carcinoma, Advanced basal cell carcinoma requiring systemic treatment
Evaluation of a Low-fluoride Anticaries Toothpaste

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to evaluate the anticaries remineralizing potential of a toothpaste containing 500 ppm fluoride plus fTCP technology relative to a commercially available toothpaste via a double-blind cross-over in situ (or intra-oral) clinical model, whereby approved human participants will wear an orthodontic appliance fitted with an enamel specimen for the duration of a leg (28 days). There will be two test legs.

Official Title
-----------------
Evaluation of a Low-fluoride Anticaries Toothpaste Containing an Innovative Calcium Technology

Conditions
-----------------
Tooth Abnormality

Intervention / Treatment
-----------------
* Drug: Fluorides, Topical


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 30 adult subjects (between 18-50 years of age)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| G1<br>500 ppm F Test Toothpaste | Drug: Fluorides, Topical<br>* 500 ppm F and 1100 ppm F topical toothpastes comprise sodium fluoride in each.<br>|
| G2<br>1100 ppm F Control Toothpaste | Drug: Fluorides, Topical<br>* 500 ppm F and 1100 ppm F topical toothpastes comprise sodium fluoride in each.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surface Microhardness | Strength measurements made at the enamel surface of the enamel specimen | 30 days | 
| Transverse Microradiography | X-ray analysis of enamel lesion | 30 days | 
| Cross-Sectional Microhardness | Strength measurements made within the enamel lesion of the enamel specimen | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anti-erosion dental benefits
Neurotoxic Health Hazards of Long-Term Low-Level Exposure to Organophosphate (OP) Compounds in in Hula Valley

Study Overview
=================
Brief Summary
-----------------
During 1987-1991, WHO supported studies of exposures and short term neurobehavioral effects in a cohort (n=200) with occupational and community exposures to pesticide drift containing organophosphates from orchards and cotton fields in the Hula Valley. We aim (1) to re-examine neurobehavioral outcomes in members of the original cohort and (2) to examine cognitive effects in children with residential exposures. In adults, we will carry out assays of alkyl phosphates, PON1 (paraoxonase-1), NTE (Neuropathy Target Esterase), neurobehavioral tests of cognitive and performance skills, nerve conduction measurements and mood status. We will carry out Psycho-Didactic tests in children. The findings will advance knowledge on delayed term health effects of lengthy everyday exposure to OP pesticides and guide regulatory policy.

Conditions
-----------------
Peripheral Neuropathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants of the former study twenty years ago
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Agricultural Workers | |
| 2<br>Non - Agricultural Workers | |
| 3<br>Kibbitz Residents working else where | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
OP, Pesticides, Long-Term Low Level Exposure, Occupational Health, Neurobehavioral Effects
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA） for liver cancer.

Detailed Description
-----------------
By enrolling patients with liver cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA） for liver cancer.

Official Title
-----------------
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Cancer: Clinical Trial

Conditions
-----------------
Liver Cancer

Intervention / Treatment
-----------------
* Procedure: interventional therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age:18-80 Karnofsky performance status >60 Diagnosis of pancreatic cancer based on histology or the current accepted radiological measures. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ Will receive interventional therapy Life expectancy: Greater than 3 months Patients' routine blood test, liver function and kidney function have no obvious abnormalities Ability to understand the study protocol and a willingness to sign a written informed consent document Exclusion Criteria: Patients with other primary tumor except pancreatic cancer History of coagulation disorders or anemia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HepaSphere<br>liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA） | Procedure: interventional therapy<br>* liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）<br>|
| No Intervention: control<br>liver cancer patients did not receive any interventional therapy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with Adverse events |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of lesions interventional therapy that show no sign of recurrence 12 months after |  | 1 year | 
| Progress free disease (PFS) |  | 1 year | 
| Overall survival (OS) |  | 3 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Liver Cancer, HepaSphere
Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the gastrointestinal tolerability of an investigational drug to an approved drug in the treatment of osteoarthritis during one year treatment period.

Detailed Description
-----------------
The duration of treatment is 12 months.

Official Title
-----------------
A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Drug: MK0663, etoricoxib
* Drug: Comparator: Diclofenac sodium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Osteoarthritis of the knee, hip, hand or spine which requires the use of medications for pain relief Exclusion Criteria: Known allergies to the study drugs

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0663, etoricoxib|nan|
|Drug: Comparator: Diclofenac sodium|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Discontinuations due to clinical and laboratory gastrointestinal adverse experiences during a 1 year treatment period. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Arcoxia
Referred vs Spontaneous Visits at Pediatric ER: an Outcome Study

Study Overview
=================
Brief Summary
-----------------
Since 80's, admissions in Emergency medical services increase regularly. Children represents 30% of the patients in Emergency medical Service. Only 20% of admissions are hospitalized and only 3 % need emergency care. Consequences are team's exhaustion, a reduction of healthcare quality, a slowdown in emergency care. Investigator decided to realize an epidemiologic prospective study in Emergency medical and surgical Pediatric Service in Strasbourg Teaching Hospital to compare coverage of children who are referred by a liberal doctor with children who are coming by themselves matched with age and complaint. This study will analyze the relevance of complaints and decision-making factors for the liberal doctor to send children in Emergency Medical and Surgical Service. Investigator will talk about the importance of close collaboration between liberal doctor and hospital doctor, as well as patient's information about basic care service on nights and week-ends in order to decrease the number of emergency admission.

Official Title
-----------------
Coverage and Future of Children Referred by a Liberal Doctor's Letter to Pediatric Emergency in Strasbourg Teaching Hospital Compared With Children Who Are Coming by Themselves in 2017

Conditions
-----------------
Emergency Surgical

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any child attending the pediatric medical and surgical emergency department of Strasbourg University Hospital, accompanied by at least one of his parents. Age of the patient: from birth to 18 years. Patient sent by mail from a liberal doctor (general practitioner, liberal pediatrician, PMI, SOS doctor ...) for the first group. Or emergency consultant spontaneously for the second group. Understanding and speaking French Having agreed to participate in the study if it is old, or whose parents have agreed to participate in the study. Exclusion Criteria: Patient unaccompanied by one of his parents Refusal to participate in the study. Vital emergency or immediate care needed Patient arriving at the emergency department at first alone with paramedics or the SMUR, then joined by his parents secondarily Patients referred by a liberal doctor but without mail.

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective study of hospitalization frequency |  | The period from January 1st, 2016 to December 31st, 2017 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pediatric, emergency surgical and medical service, Liberal doctor, complaint
Correlation Between Umbilical Resistance Index and Fetal Growth

Study Overview
=================
Brief Summary
-----------------
The aim of our study was to investigate the correlation between the umbilical resistance index and weight gain during the third trimester of low-risk pregnancies.

Official Title
-----------------
Correlation Between Umbilical Resistance Index and Fetal Growth: a Pilot Study

Conditions
-----------------
Umbilical Doppler

Intervention / Treatment
-----------------
* Other: ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any pregnant patient with a normally progressing pregnancy and reporting for a prenatal screening ultrasound between 31 and 34 weeks amenorrhea. Exclusion Criteria: -The lack of an ultrasound carried out during the first trimester to confirm the term of the pregnancy. A medical condition in the mother: diabetes, high blood pressure or a known chronic illness. A medical condition in the fetus: suspicion of fetal hypotrophy (fetal biometrics lower than the 10th percentile), a birth defect (a chromosomal abnormality) during the pregnancy. Patients with tobacco addiction. A body mass index (BMI) ≥ 30 before the pregnancy. Multiple pregnancies A gap of less than 4 weeks between the date of the ultrasound and the date of delivery.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: ultrasonography|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fetal growth | . During routine prenatal third trimester ultrasonography patients had a fetal weight estimation and measurement of the umbilical resistance index. After delivery we took note of the weight at birth, the term of the delivery, and the time interval between the ultrasound and the delivery, and then we calculated the weight gain on a weekly basis. | at birth | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ultrasound; umbilical Doppler; resistance index; fetal growth
Sensory Examination and Pharmacological Modulation of Oral Hyperexcitability in Patients With Atypical Odontalgia and Matched Healthy Controls

Study Overview
=================
Brief Summary
-----------------
This project examines experimental pain and chronic pain in the mouth, specifically the condition called atypical odontalgia (AO:atypical toothpain). In 16 patients with AO and 16 healthy persons, capsaicin (chili-pepper) is applied to the gingiva to cause pain. This pain is evaluated by the participants. In three sessions, 3 different medications are tested for effect on the pain. The medications are fentanyl, S-ketamine and placebo-treatment (saline). The aim is to know more about pain mechanisms in AO in order to develop an effective treatment.

Conditions
-----------------
Odontalgia

Intervention / Treatment
-----------------
* Drug: fentanyl
* Drug: S-ketamine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Atypical odontalgia Exclusion Criteria: BMI > 30 Heart conditions Lung disease Diseases of the liver or kidneys Hypertension, untreated

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: fentanyl|nan|
|Drug: S-ketamine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain |  |  | 
| Sensitivity to heat and cold |  |  | 
| Sensitivity to mechanical stimuli |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atypical odontalgia, capsaicin, pain, neuropathic pain